References
- Wang H, Wu J, Guo W. SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12. Onco Targets Ther. 2020;13:4305–18. doi:https://doi.org/10.2147/OTT.S242854.
- Li X-Y, Huang G-H, Liu Q-K, Yang X-T, Wang K, Luo W-Z, et al. Porf-2 Inhibits Tumor Cell Migration Through the MMP-2/9 Signaling Pathway in Neuroblastoma and Glioma. Front Oncol. 2020;10:975. doi:https://doi.org/10.3389/fonc.2020.00975.
- Zhao B, Meng L-Q, Huang H-N, Pan Y, Xu Q-Q. A novel functional polymorphism, 16974 A/C, in the interleukin-12-3' untranslated region is associated with risk of glioma. DNA Cell Biol. 2009;28(7):335–41. doi:https://doi.org/10.1089/dna.2008.0845.
- Chang C-Y, Pan P-H, Li J-R, Ou Y-C, Wang J-D, Liao S-L, et al. Aspirin induced glioma apoptosis through Noxa Upregulation. Int J Mol Sci. 2020;21(12):4219. doi:https://doi.org/10.3390/ijms21124219.
- Zhang Q, Zhong H, Fan Y, Liu Q, Song J, Yao S, et al. Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis. Front Bioeng Biotechnol. 2020;8:592. doi:https://doi.org/10.3389/fbioe.2020.00592.
- Wang F, Zhou Y, Cheng S, Lou J, Zhang X, He Q, et al. Gint4.T-Modified DNA Tetrahedrons Loaded with Doxorubicin Inhibits Glioma Cell Proliferation by Targeting PDGFRβ. Nanoscale Res Lett. 2020;15(1):150. doi:https://doi.org/10.1186/s11671-020-03377-y.
- Xiao L, Li X, Mu Z, Zhou J, Zhou P, Xie C, et al. FTO inhibition enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma . Cancer Res. 2020;80(18):3945–58. doi:https://doi.org/10.1158/0008-5472.
- Cai H, Liu W, Liu X, Li Z, Feng T, Xue Y, et al. Advances and prospects of vasculogenic mimicry in glioma: a potential new therapeutic target? Onco Targets Ther. 2020;13:4473–83. doi:https://doi.org/10.2147/OTT.S247855.
- Li Y, et al. Downregulation of LUZP2 is correlated with poor prognosis of low-grade glioma. Biomed Res Int. 2020;2020:9716720.
- Yuan J, Zhang N, Zheng Y, Chen Y-D, Liu J, Yang M, et al. LncRNA GAS5 indel genetic polymorphism contributes to glioma risk through interfering binding of transcriptional factor TFAP2A. DNA Cell Biol. 2018;37(9):750–7. doi:https://doi.org/10.1089/dna.2018.4215.
- da Silveira F. d C A, Lopes B. d A, da Fonseca CO, Quirico-Santos T, de Palmer Paixão ICN, de Amorim L. M d F, et al. Analysis of EGF + 61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy. J Cancer Res Clin Oncol. 2012;138(8):1347–54. doi:https://doi.org/10.1007/s00432-012-1203-5.
- Chen X, Zhao T, Li L, Xu C, Zhang X, Tse V, et al. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol. 2012;31(6):1107–13. doi:https://doi.org/10.1089/dna.2011.1521.
- Permuth-Wey J, Thompson RC, Burton Nabors L, Olson JJ, Browning JE, Madden MH, et al. A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J Neurooncol. 2011;105(3):639–46. doi:https://doi.org/10.1007/s11060-011-0634-1.
- Dou T, Wu Q, Chen X, Ribas J, Ni X, Tang C, et al. A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. J Cancer Res Clin Oncol. 2010;136(12):1853–9. doi:https://doi.org/10.1007/s00432-010-0844-5.
- Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000;9(8):843–7.
- Zhang L, Qiu Z, Luo J, Shu W. X-ray repair cross-complementing gene 1 Arg399Gln polymorphism and glioma risk among Asians: A meta-analysis based on 2 326 cases and 3 610 controls. Neural Regen Res. 2012;7(29):2313–9. doi:https://doi.org/10.3969/j.issn.1673-5374.2012.29.011.
- Xu H, Chai S, Wang Y, Wang J, Xiao D, Li J, et al. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target. CNS Neurosci Ther. 2020;26(8):804–14. doi:https://doi.org/10.1111/cns.13380.
- Zhang J, Zhou L, Nan Z, Yuan Q, Wen J, Xu M, et al. Knockdown of c‐Myc activates Fas-mediated apoptosis and sensitizes A549 cells to radiation . Oncol Rep. 2017;38(4):2471–9. doi:https://doi.org/10.3892/or.2017.5897.
- Dong H, Adams NM, Xu Y, Cao J, Allan DSJ, Carlyle JR, et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. Nat Immunol. 2019;20(7):865–78. doi:https://doi.org/10.1038/s41590-019-0388-z.
- Xu L, Wang L, Zhou L, Dorfman RG, Pan Y, Tang D, et al. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming. Neoplasia. 2019;21(5):429–41. doi:https://doi.org/10.1016/j.neo.2019.03.002.
- Basit F, Andersson M, Hultquist A. The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease. Stem Cells Int. 2018;2018:3286949. doi:https://doi.org/10.1155/2018/3286949.
- Lee Y-S, Heo W, Son C-H, Kang C-D, Park Y-S, Bae J, et al. Upregulation of Myc promotes the evasion of NK cell‐mediated immunity through suppression of NKG2D ligands in K562 cells. Mol Med Rep. 2019;20(4):3301–7. doi:https://doi.org/10.3892/mmr.2019.10583.
- Qin Y, Hu Q, Xu J, Ji S, Dai W, Liu W, et al. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Commun Signal. 2019;17(1):30. doi:https://doi.org/10.1186/s12964-019-0344-4.
- Loftus RM, Assmann N, Kedia-Mehta N, O'Brien KL, Garcia A, Gillespie C, et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun. 2018;9(1):2341. doi:https://doi.org/10.1038/s41467-018-04719-2.
- Su B, Xu T, Bruce JP, Yip KW, Zhang N, Huang Z, et al. hsa‐miR‐24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‐Myc/epithelial‐mesenchymal transition axis. Oncol Rep. 2018;40(5):2536–46. doi:https://doi.org/10.3892/or.2018.6690.
- Sakr HI, Chute DJ, Nasr C, Sturgis CD. cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis. Diagn Pathol. 2017;12(1):71. doi:https://doi.org/10.1186/s13000-017-0661-0.
- Huang X, Zhao J, Fu W, Zhu J, Lou S, Tian X, et al. The association of RAN and RANBP2 gene polymerphisms with Wilms tumor risk in Chinese children. J Cancer. 2020;11(4):804–9. doi:https://doi.org/10.7150/jca.36651.
- Cheng J, Zhuo Z, Xin Y, Zhao P, Yang W, Zhou H, et al. Relevance of XPD polymorphisms to neuroblastoma risk in Chinese children: a four-center case-control study. Aging. 2018;10(8):1989–2000. doi:https://doi.org/10.18632/aging.101522.
- Liu J, Hua R-X, Fu W, Zhu J, Jia W, Zhang J, et al. MYC gene associated polymorphisms and Wilms tumor risk in Chinese children: a four-center case-control study. Ann Transl Med. 2019;7(18):475. doi:https://doi.org/10.21037/atm.2019.08.31.
- Pan J, Zhu J, Wang M, Yang T, Hu C, Yang J, et al. Association of MYC gene polymorphisms with neuroblastoma risk in Chinese children: A four-center case-control study. J Gene Med. 2020;22(8):e3190. doi:https://doi.org/10.1002/jgm.3190.
- Yang T, Wen Y, Li J, Tan T, Yang J, Pan J, et al. Association of CMYC polymorphisms with hepatoblastoma risk. Transl Cancer Res Tcr. 2020;9(2):849–55. doi:https://doi.org/10.21037/tcr.2019.12.19.
- Wang J, Zhuo Z, Chen M, Zhu J, Zhao J, Zhang J, et al. RAN/RANBP2 polymorphisms and neuroblastoma risk in Chinese children: a three-center case-control study. Aging. 2018;10(4):808–18. doi:https://doi.org/10.18632/aging.101429.
- Hua R-X, Zhuo Z, Ge L, Zhu J, Yuan L, Chen C, et al. LIN28A gene polymorphisms modify neuroblastoma susceptibility: A four-centre case-control study. J Cell Mol Med. 2020;24(1):1059–66. doi:https://doi.org/10.1111/jcmm.14827.
- Zhang Z, Yin J, Xu Q, Shi J. Association between the XPG gene rs2094258 polymorphism and risk of gastric cancer. J Clin Lab Anal. 2018;32(8):e22564. doi:https://doi.org/10.1002/jcla.22564.
- Chen P, Guo X, Zhang L, Zhang W, Zhou Q, Tian Z, et al. MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN. Oncotarget. 2017;8(3):5206–18. doi:https://doi.org/10.18632/oncotarget.14123.
- Day AH, Übler MH, Best HL, Lloyd-Evans E, Mart RJ, Fallis IA, et al. Targeted cell imaging properties of a deep red luminescent iridium(iii) complex conjugated with a c-Myc signal peptide. Chem Sci. 2020;11(6):1599–606. doi:https://doi.org/10.1039/c9sc05568a.
- Liu Y, Timani K, Mantel C, Fan Y, Hangoc G, Cooper S, et al. TIP110/p110nrb/SART3/p110 regulation of hematopoiesis through CMYC. Blood. 2011;117(21):5643–51. doi:https://doi.org/10.1182/blood-2010-12-325332.
- Zhong C, Fan L, Li Z, Yao F, Zhao H. SREBP2 is upregulated in esophageal squamous cell carcinoma and co‐operates with c‐Myc to regulate HMGCR expression. Mol Med Rep. 2019;20(4):3003–10. doi:https://doi.org/10.3892/mmr.2019.10577.
- Luo G, Li B, Duan C, Cheng Y, Xiao B, Yao F, et al. c‐Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway. Oncol Rep. 2017;38(4):2498–506. doi:https://doi.org/10.3892/or.2017.5913.
- Zaharieva B, Simon R, Ruiz C, Oeggerli M, Mihatsch MJ, Gasser T, et al. High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer. 2005;117(6):952–6. doi:https://doi.org/10.1002/ijc.21253.
- Berberich A, Schmitt L-M, Pusch S, Hielscher T, Rübmann P, Hucke N, et al. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. J Neurooncol. 2020;146(1):9–23. doi:https://doi.org/10.1007/s11060-019-03348-z.
- Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. J Neurooncol. 2013;115(2):249–59. doi:https://doi.org/10.1007/s11060-013-1221-4.